48 funding opportunities found in this category. Change the order of results: Newest First Oldest First Expiring Soonest Expiring Latest Lowest Award to Highest Highest Award to Lowest
Lustgarten Foundation Research Funding Opportunities
Concept Due Date: May 24, 2013
Full Applications Due: August 9, 2013
Funding to begin January 2014
The Lustgarten Foundation (LF) is the nation’s largest private funder of pancreatic cancer research. Our mission is to advance scientific and medical research related to the diagnosis, treatment, cure and prevention of pancreatic cancer. Thanks to the support of Cablevision, 100% of all our donations go directly to research, which has enabled us to commit $65 Million to outstanding research projects to date.
For the 2013 Grant application cycle, The Foundation’s Scientific Review Board has identified a number of research areas for which proposals are now being solicited (below).
Research Topics
Clinical/Translational RFA's
Early Detection and Risk Assessment in Pancreas Cancer
New Drug Delivery Approaches in Pancreas Cancer
Novel Imaging Technologies in Pancreas Cancer
Novel Therapeutic Agents in Pancreas Cancer
Correlative Studies Awards Program
Preclinical RFA's
Novel Agents for Pancreas Cancer
Clinical and Molecular Markers of Metastic Burden
Basic RFA's
Immune Surveillance and Modulation
Early Stage Target Validation for Pancreas Cancer
Impact of Chromatin Alteration in Pancreas Cancer
New Models of PDAC
Requests for Applications: Biomarkers of Pancreatic Beta Cell Stress and Health
JDRF, the world’s leading non-profit organization with the mission to cure type 1 diabetes (T1D), invites applications from research investigators having interest and expertise to support the discovery and advancement of biomarkers of pancreatic beta cell stress and health correlating with early beta-cell loss.
The purpose of this call for Letters of Intent is to invite proposals to support and advance the discovery, development, and/or validation of biomarkers of pancreatic beta cell stress and dysfunction. Studies based on use or validation with human beta cells/islets and clinical samples or tissues will be of special interest.
MECHANISM
Applications in response to this announcement can be submitted under one of the following funding mechanisms: Pilot & Feasibility Grants (P&Fs): up to $110,000 (including 10% indirect costs) for one year only.
Strategic Research Agreements (SRAs): Up to $250,000 USD per year including 10% indirect costs for up to 3 years may be requested. The level of funding will vary depending on the scope and overall objectives of the proposal. Under the terms of the grant award, written quarterly (~2-3 pages) reports will be required from the funded investigator as a basis for continued support.
LETTER OF INTENT
Prospective applicants should submit a letter of intent on -line via the proposalCENTRAL website (https://proposalcentral.altum.com/default.asp).
The LOI template provided on the proposalCENTRAL Web site must be used to complete the application. Applicants will be notified approximately eight weeks after the LOI deadline date if they have been approved to submit a full application.
Letter of Intent Deadline: June 17, 2013.
Call for Applications: Meso Foundation Research Grants
The Meso Foundation (formerly known as MARF) is the non-profit dedicated to ending the suffering caused by mesothelioma. We are the international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to:
· Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso treatment specialists, and providing them assistance, emotional support and community with others;
· Raise awareness of meso, and advocate that the public and private sectors partner in the effort to cure it by directing the resources needed to stop this global tragedy; and
· Fund the highest quality and most promising meso research projects from around the world through rigorous peer-review. To date we have funded 86 projects, from six different countries, totaling over 8.2 million dollars.
The Meso Foundation offers research grants for two years up to $50,000 per year. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded or pending review and may be conducted through any not-for-profit academic, medical or research institution. The Foundation will review and monitor the project's progress and results, requiring semi-annual disposition of funds reports, a ten month progress report, a presentation at the Foundation’s Symposium and a full progress report at the close of the project. The Foundation seeks exceptional projects for which the Foundation's funding is demonstrated to be essential and not duplicative. Please be advised that the Foundation does not pay institutional indirect costs.
Funded researchers will also be entitled to facilitated access to the National Mesothelioma Virtual Bank (NMVB),www.mesotissue.org.They will receive expedited review of requests to use the NMVB, and they will have direct, no-cost access to materials in the bank, as well as enhanced collections from the main sites of materials.
Encouraged projects include, but are not limited to, investigations of:
1. Strategies for early detection of new or progressive disease;
2. Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment;
3. Therapeutic intervention, including but not limited to;
a. Immune Response Targeted Therapy
b. Novel chemotherapeutic compounds
c. Novel radiation or surgical techniques
4. Determination of clinical/molecular determinants for prognosis
Applications will be considered for funding by the Meso Foundation’s Science Advisory Board comprised of doctors and researchers who work around the world within the mesothelioma field. These members will review and score the research proposals based on the following criteria. The applications will be ranked numerically and the highest scoring projects will be recommended to the Foundation’s Board of Directors for funding. Based on the funding available, awards will be granted.
Applications will be evaluated on the following criteria:
Significance - Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Investigator(s)- Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Innovation - Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach - Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, justified in terms of the scientific goals and research strategy proposed?
Environment - Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Applications should be submittedthrough proposalCENTRAL.You will find the Mesothelioma Applied Research Foundation listed with the instructions and the application required. Applications are limited to 10 pages (not including biographies) and are due no later than August 2, 2013. Final award decisions will be made in December 2013 and all applicants will be notified of the outcome.
Travel Grants for the 4th International Thymic Malignancy Interest Group Annual Meeting (ITMIG 2013)
September 6 - 7, 2013 Bethesda, Maryland
This important Conference will highlight the latest scientific and clinical developments related to the management of thymic malignancies and will bring together established scientists and clinicians from all over the world who have interest in the field of thymic cancers research.
The Conference is pleased to offer travel grants to trainees, residents and fellows.
Eligible Candidates
Trainee, resident or fellow - proof of status required
Submitting and presenting author for an abstract accepted at ITMIG 2013
Benefits
Complimentary full Conference registration
Cash award to help offset travel expenses
Supporting Application Materials
Curriculum Vitae Recommendation/Supporting Letter from supervisor Proof of status (trainee, resident, fellow)
How to Apply?
Send application email including supporting materials to itmig2013@icsevents.com by June 14, 2013
Submit abstract via online abstract submission form by June 14, 2013
Terms and Conditions The organizers reserve the right to
Cancel the scholarship if a selected award winner is not attending in person
Amend the terms and conditions of the scholarship program without notice
Deadlines and Timelines
Application Deadline: June 14, 2013
Notifications: expected to be available end of July 2013
Contact
For any questions or inquries regarding travel grants, please contact the Conference Secretariat at itmig2013@icsevents.com.
2013 ASPIRE Rheumatology Research Awards
As competition for research funding increases, the ASPIRE program underscores Pfizer's commitment to supporting research in rheumatologic diseases.
Mission
The mission of the 2013 ASPIRE program is to support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the epidemiology, pathogenesis and treatment of selected diseases.
The ASPIRE Program demonstrates Pfizer’s commitment to supporting promising investigators with an interest in advancing knowledge in defined disease areas including rheumatologic diseases.
Scientific research continues to advance our knowledge and understanding of rheumatologic diseases. The 2013 ASPIRE Rheumatology Research Awards are designed to fund research proposals aimed to further the understanding of certain rheumatologic conditions and contribute to excellence in patient care.
Areas of Focus
Research areas of interest are as follows:
• Biomarker development/validation using patient-derived material
• Studies to improve diagnosis, prognosis or treatment
• Imaging in early diagnosis
• Imaging in treatment monitoring
• Patient-Reported Outcomes
• Impact of Discordance Between Patient and Physician Ratings of Disease Activity on Outcomes
Available Awards
Pfizer is funding research awards up to a maximum of $75,000 USD per-annum for up to 2 years (maximum total of an award over the 2 years of funding is $150,000).
Applicants
To be eligible for an award, applicants must:
• have a professional degree (MD, PhD, PharmD or equivalent)
• reside in the United States
Deadline for Application
• Applications must be received by July 1, 2013, 11:59pm EDST
• Addenda, supplemental materials, changes, or updates will not be accepted after the deadline
• Notification of Awards recipients will be in August 2013
How to Apply
Applications are to be submitted to Pfizer through an online submission website.
2013 ASPIRE Hemophilia Research Awards
As competition for research funding increases, the ASPIRE HEMOPHILIA program underscores Pfizer’s commitment to supporting investigators with an interest in advancing their academic research careers in Hemophilia A & B.
The mission of the ASPIRE Program is as follows.
• To support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the pathogenesis and treatment of hemophilia.
•To support academic research as well as the career development of promising young and established scientists.
Basic science and clinical research continue to advance our knowledge and understanding of Hemophilia A and Hemophilia B. However, the clinical applicability of these findings is not always apparent and correlative studies may not be readily available.
The ASPIRE HEMOPHILIA program is designed to support basic science and clinical research in Hemophilia pathogenesis, host response and clinical outcomes in Hemophilia A and Hemophilia as well as translation of the resulting knowledge to bridge the gap between bench and bedside.
It is hoped that the results will lead to a better understanding of disease mechanisms and treatment options to enhance the clinical care of patients with Hemophilia A or Hemophilia B
Areas of Focus: Hemophilia A and Hemophilia B
Pfizer will support competitive grant programs which address one of the following areas in Hemophilia A and/or Hemophilia B.
Application is open to US investigators. Selection of research proposals will be performed by an independent, external expert panel comprised of nationally known academic clinicians. Project duration should be 1-2 years and should be approximately $125,000/year, inclusive of overhead costs.
To be eligible for an ASPIRE Hemophilia award, applicants must:
• have a doctoral degree (MD, PhD, PharmD, or equivalent);
• reside and practice in the United States.
• Applications must be received by Monday, May 20, 2013, 11:59 PM Eastern Daylight Time
• Award decisions will be made in July 2013
• Successful applicants will be notified in July/August 2013
• The final study results or an interim progress report is expected on or before December 31, 2014
Applications should be submitted through the online submission website.
Questions
questions.aspireresearch-HEMOPHILIA@pfizer.com
Amyloidosis Foundation 2013 Senior Research Grant
History of the Amyloidosis Foundation: The Amyloidosis Foundation is a result of the merge of the Amyloidosis Research Foundation and the Amyloidosis Support Network in 2007. The ARF’s original mission was to support research for all types of amyloidosis and the ASN’s original mission was to increase awareness of the disease and support patients with information. The new organization maintains both missions with the intent of expanding our services to both patients and the medical and scientific community.
Eligibility
The grant program supports two research areas, basic scientific research and translational research. Applicants will have completed their doctoral studies or clinical fellowship more than ten (10) years prior to application to this program. Although a mentor is not a requirement, the involvement of one will be considered in the feasibility review of the proposal.
Submission Deadline/Confirmation
Complete applications must be received by August 1, 2013. You will receive a confirmation email or fax from the AF upon receipt of your application.
Selection and Considerations
The selection of the recipient(s) will be made by the Board of Directors of the foundation, after all applications have been reviewed by the Scientific Advisory Board, consisting of experts in the field of amyloidosis. Candidates are strictly prohibited from contacting any members of the advisory board regarding status of their application.
The committee will consider most favorably those proposals that provide evidence of an applicant’s research initiative and creativity. The committee will also consider the feasibility of meaningful results from the proposed research, and the likely contribution to the advancement of knowledge of Amyloidosis etiology, diagnosis, treatment, or prevention.
Selection Notification
All candidates will receive notification from the AF office of the final selection of the recipient(s) via email or mail. The award announcement for this grant cycle will be no later than December 1, 2013.
Award Conditions and Reporting
The monetary award of $100,000US will be provided to the awardee's sponsoring institution in two payments of $50,000US for the direct support of the recipients work during the award year, which will begin January 1, 2014. Acknowledgement of receipt of the funds and date of receipt is required of the sponsoring institution.
At the mid point of the year, a brief update report must be submitted to the AF. This report is required prior to the release of the remaining funds. At the conclusion of the award year, the recipient is required to submit a brief written summary of the research conducted.
Recipients are expected to credit the foundation in any publications or presentations that result from the funded research.
Amyloidosis Foundation, Inc. 7151 N. Main St. Suite 2 Clarkston, MI 48346
Phone: 1-877-AMYLOID info@amyloidosis.org
Amyloidosis Foundation 2013 Junior Research Grant
The grant program supports two research areas, basic scientific research and translational research. Applicants will have completed their doctoral studies or clinical fellowship within ten (10) years prior to application to this program. Although a mentor is not a requirement, the involvement of one will be considered in the feasibility review of the proposal.
The monetary award of $50,000US will be provided to the awardees sponsoring institution in two payments of $25,000US for the direct support of the recipients work during the award year, which will begin January 1, 2014. Acknowledgement of receipt of the funds and date of receipt is required of the sponsoring institution.
Call for Proposals: NCL Research Award for Research on Batten Disease
The NCL Foundation provides regulary the NCL research award. The goal is to find a cure against the deadly children's disease Neuronal Ceroid Lipofuscinosis (NCL), also called Batten disease. This metabolic disorder is the most common neurodegenerative disease of childhood and is inevitably fatal. The gradual stages of the suffering are blindness, dementia, epilepsy, loss of speech, paralysis and complete helplessness.
We invite medical and basic science researchers worldwide to submit innovative clinical oriented or translational basic science projects, which can contribute to finding a cure for juvenile NCL.
Scientists from related areas of science including Alzheimer's disease, aging, and other lysosomal storage disorders, are particularly encouraged to apply with the aim to extend the NCL research community in move more efficiently towards a cure for NCL.
NCL Research Award 2013
This year, the NCL Foundation offers for the fifth time the NCL Research Award.
Grant monies (100,000 euros) are to be used for a postdoctoral fellowship in order to undertake the research project. In this fashion our goal is to promote the next generation of young NCL research scientists.
The deadline for applications: October 31, 2013
Please send the required documents to: Research@ncl-foundation.com
Call for Applications: Grass Foundation - American Neurological Association Award in Neuroscience
The Grass Foundation and the American Neurological Association (ANA) are now accepting nominations for The Grass Foundation – ANA Award in Neuroscience. This Award was established in 2007 to honor outstanding young investigators doing research in basic or clinical neuroscience. The Grass Foundation www.grassfoundation.org was established in 1955 by Albert and Ellen Grass to advance research and education in neuroscience, with a special focus on investigators early in their careers.
Candidates include:
• physician-scientist neurology faculty members early in their careers (MD or MD/PhD)
• who are 5 years or less out of postgraduate or post fellowship training
• conducting research in neuroscience
Award
The awardee will receive:
• $1,000 honorarium
• inclusion in the scientific program of the ANA’s Annual Meeting as either a poster or platform presenter
• gratis Annual Meeting registration
• up to $1,500 travel reimbursement
• a commemorative plaque
Nomination Process
To submit a nomination, please send a letter of recommendation and the nominee’s CV and bibliography to ana@llmsi.com. Both self-nominations and nominations from second parties will be accepted.
All nomination materials must be submitted by February 15th of each year.
12345next
